Treatment of Post-Allogeneic HCT Relapsed AML/MDS with a Combination of Hypomethylating Agent, Venetoclax (HMA/VEN) and Donor Lymphocyte Infusion (DLI)

There is no standard of care for relapsed myeloid neoplasms (acute myeloid leukemia- AML/myelodysplastic syndrome-MDS) after allogeneic hematopoietic cell therapy (HCT). Intensive chemotherapy has been ineffective/toxic and DLI alone has had modest responses in this setting. When one compares DLI to second allogeneic HCT the responses are equivalent. More recently there is evidence in AML that HMA/VEN combination produces remission even in relapsed disease. In this retrospective analysis we reviewed patients with AML/MDS who relapsed post HCT and received (HMA+/-VEN) followed by DLI.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Stanislav A Ivanov, Yehuda E Deutsch, Jennifer Logue, Jose Sandoval Sus, Carlos Silva, Nina Nguyen, Claudia E Paba Prada, Fernando Vargas Madueno, Hugo F Fernandez Tags: 556 Source Type: research